Bio-Rad Laboratories (FRA:BUWA) Inventories, Finished Goods: €274 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
70 GF Score
Price €327.80
GF Value €276.85
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Inventories, Finished Goods?

Bio-Rad Laboratories FRA:BUWA -1.50% 70 Inventories, Finished Goods is €274 Mil as of Jun. 2026. GuruFocus rates FRA:BUWA with a GF Score™ of 70/100 and a GF Value™ of €276.85 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Bio-Rad Laboratories's quarterly finished goods increased from Dec. 2025 (€250 Mil) to Mar. 2026 (€286 Mil) but then declined from Mar. 2026 (€286 Mil) to Jun. 2026 (€274 Mil).

Bio-Rad Laboratories's annual finished goods increased from Dec. 2023 (€278 Mil) to Dec. 2024 (€282 Mil) but then declined from Dec. 2024 (€282 Mil) to Dec. 2025 (€250 Mil).

Bio-Rad Laboratories Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories Inventories, Finished Goods Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 227.71 254.50 277.76 281.53 250.48

Bio-Rad Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 276.14 263.69 250.48 285.71 274.29
FRA:BUWA
70GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of €274 Mil mean?
Bio-Rad Laboratories (FRA:BUWA) has a Inventories, Finished Goods of €274 Mil as of Jun. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Bio-Rad Laboratories and its competitors.
Is Bio-Rad Laboratories' Inventories, Finished Goods too high?
Bio-Rad Laboratories' current Inventories, Finished Goods is €274 Mil. Overall, Bio-Rad Laboratories has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Inventories, Finished Goods compare to PODD and GKOS?
Bio-Rad Laboratories' Inventories, Finished Goods of €274 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Medical Devices & Instruments company?
A good Inventories, Finished Goods depends on the Medical Devices & Instruments industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current Inventories, Finished Goods is €274 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Modestly Overvalued. The stock's GF Value™ is €276.85, compared to a current price of €327.80 — trading 18.4% above its estimated fair value. The current Inventories, Finished Goods is €274 Mil. Bio-Rad Laboratories' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Inventories, Finished Goods is €274 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued. The current stock price of €327.80 is trading 18.4% above its estimated GF Value™ of €276.85. GuruFocus considers Bio-Rad Laboratories to be Modestly Overvalued.

Key valuation signals for FRA:BUWA:

  • Inventories, Finished Goods: €274 Mil
  • GF Value™: €276.85 vs. price of €327.80 (18.4% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
70GF Score

Get the complete analysis for FRA:BUWA

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€327.80
Price
€276.85
GF Value